Health

EU drug regulators to discuss Merck COVID-19 antiviral pill next week

European Union drug regulators said they will discuss Merck & Co.’s antiviral pill next week amid a report that the drug faces potential rejection.

A panel of the European Medicines Agency will consider the drug’s effectiveness at the meeting, Marco Cavaleri, the regulator’s head of biological health threats and vaccines strategy, said at a briefing on Thursday. He declined to comment on the robustness of the evidence to back the pill.

For the latest headlines, follow our Google News channel online or via the app.

The US drugmaker has been developing molnupiravir with partner Ridgeback Biotherapeutics LP.

The pill is only about 30 percent effective at preventing COVID-19 deaths and hospitalizations among high-risk patients, compared with about 90 percent efficacy for Pfizer Inc.’s Paxlovid, studies have shown.

The Financial Times reported Wednesday that the antiviral is unlikely to get EMA approval, citing people it didn’t identify familiar with the situation.

Merck on February 3 trimmed the upper end of its 2022 forecast of molnupiravir sales to $6 billion, down from its earlier prediction that the drug might log up to $7 billion by yearend.

China approves Pfizer’s COVID pill Paxlovid for mild to moderate cases

Pfizer confirms experimental COVID pill appears effective against omicron variant

Health

World News in Brief: Vaccine ‘patches’ trial shows promise, lowering catheter infection risk, Guantanamo detainee facing revictimisation

Few enjoy having injections and if you have children, you probably like them even less when it’s time for their mandated vaccine shots.

Health

No sign yet of H5N1 bird flu spreading between humans, says WHO chief

The H5N1 avian influenza virus has so far shown no signs of adapting to allow human to human transmission, the UN health agency said on Wednesday, urging continued surveillance.

Health

Patients in Rafah ‘afraid to seek services’, WHO reports

The World Health Organization (WHO) has taken “crucial steps” in the event of a large-scale Israeli military operation in Rafah, Dr. Ahmed Dahir, Team Lead of its office in Gaza, told UN News on Tuesday.